Journal of Hand Therapy
Volume 23, Issue 2 , Pages 158-172 , April 2010

Screening for Medical Disease—Nervous System Disorders

  • Michelle H. Cameron, MD, PT

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests to Michelle H. Cameron, MD, PT, Department of Neurology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd, CR120, Portland, OR 97239

References 

  1. Appelros P, Stegmayr B, Terent A. Sex differences in stroke epidemiology: a systematic review. Stroke. 2009;40:1082–1090
  2. Warner LE, Garcia CA, Lupski JR. Hereditary peripheral neuropathies: clinical forms, genetics, and molecular mechanisms. Annu Rev Med. 1999;50:263–275
  3. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  4. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699
  5. Evans RW. Saunders manual of neurologic practice. Philadelphia, PA: WB Saunders Co.; 2003;
  6. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 2007;54:34–66
  7. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  8. Wolf PA. Epidemiology of stroke. In:  Mohr JP,  Choi DW,  Grotta JC,  Weir B,  Wolf PA editor. Stroke: Pathophysiology, Diagnosis, and Management. London, UK: Churchill Livingstone; 2004;p. 13–34
  9. Barrett KM, Levine JM, Johnston KC. Diagnosis of stroke and stroke mimics in the emergency setting. CONTINUUM: Lifelong Learn Neurol. 2008;14:13–27
  10. Stein J. Stroke and the family: A new guide. Boston, MA: The Harvard University Press; 2004;
  11. Hart RG, Kanter MC. Hematologic disorders and ischemic stroke. A selective review. [see comment] Stroke. 1990;21:1111–1121
  12. Beers MH, Porter RS, Jones TV. The Merck manual. 18th ed.. West Point, PA: Merck & Co. Inc.; 2006;
  13. Drislane F, Acosta JA, Benatar M, Chang B, Caplan LR. Blueprints neurology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006;
  14. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40:2945–2948
  15. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Andarterectomy Trial Collaborators. N Engl J Med. 1991;325:445–453
  16. CDC injury center . Available at: http://www.cdc.gov/ncipc/tbi/tbi_congress/03_current.htm2009;(Accessed July 20, 2009)
  17. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil. 1999;14:602–615
  18. CDC . Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. Available at: http://www.cdc.gov/ncipc/pub-res/tbi_in_us_04/tbi_ed.htm2009;Accessed Jul 20, 2009
  19. Carroll LJ, Cassidy JD, Peloso PM, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on mild traumatic brain injury. J Rehabil Med. 2004;Suppl 43:84–105
  20. Greenberg H, Chandler WF. Brain tumors. Oxford, UK: Oxford University Press; 1999;
  21. Rasmussen T. Surgery of epilepsy associated with brain tumors. Adv Neurol. 1975;8:227–239
  22. Surawicz TS, Davis F, Freels S, Laws ER, Menck HR. Brain tumor survival: results from the national cancer data base. J Neurooncol. 1998;40:151–160
  23. BMJ Evidence Centre . Parkinson's disease. Available at: http://clinicalevidence.bmj.com/ceweb/conditions/nud/1203/1203_background.jsp2009;Accessed Jul 20, 2009
  24. National Institute of Neurological Disorders and Stroke . Parkinson's disease: hope through research. Available at: http://www.ninds.nih.gov/disorders/parkinsons_disease/detail_parkinsons_disease.htm2009;Accessed Jul 20, 2009
  25. American Academy of Neurology . AAN guidelines summary: detection, diagnosis and management of dementia. Available at: http://www.aan.com/professionals/practice/pdfs/dementia_guideline.pdf2009;Accessed Jul 20, 2009
  26. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003;51:1451–1454
  27. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive ‘vital signs’ measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021–1027
  28. Weytingh MD, Bossuyt PM, van Crevel H. Reversible dementia: more than 10% or less than 1%? A quantitative review. J Neurol. 1995;242:466–471
  29. Firth HV, Hurst JA, Hall GH. Oxford desk reference—Clinical genetics. Oxford, UK: OUP; 2005;
  30. Heller JL. Convulsions. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000021.htm2009;Accessed Jul 20, 2009
  31. Facts and figures at a glance . Available at: http://www.spinalcord.uab.edu/show.asp?durki=119513&site=4716&return=197752009;Accessed Jul 20, 2009
  32. Huff JS. Neoplasms, spinal cord. Available at: http://emedicine.medscape.com/article/779872-overview2009;Accessed Jul 20, 2009
  33. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–127
  34. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582
  35. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370:389–397
  36. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4:643–652
  37. Khan F, Pallant JF, Brand C, Kilpatrick TJ. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatr. 2008;79:1230–1235
  38. Storr LK, Sorensen PS, Ravnborg M. The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler. 2006;12:235–242
  39. Peripheral neuropathy fact sheet . Available at: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm2009;Accessed Jul 20, 2009
  40. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia. 2005;48:824–828
  41. Forst T, Nguyen M, Forst S, Disselhoff B, Pohlmann T, Pfutzner A. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new salutaris device. Diabetes Nutr Metab. 2004;17(3):163–168
  42. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care. 1997;20:1702–1705
  43. Newswanger DL, Warren CR. Guillain-Barre syndrome. Am Fam Physician. 2004;69:2405–2410
  44. National Institute of Neurological Disorders and Stroke. Guillain-Barré syndrome fact sheet. Available at: Guillain-Barré Syndrome Fact Sheet. Available at: http://www.ninds.nih.gov/disorders/gbs/gbs.htm. Accessed Jul 20, 2009.
  45. Gregory MA, Gregory RJ, Podd JV. Understanding Guillain-Barre syndrome and central nervous system involvement. Rehabil Nurs. 2005;30(5):207–212
  46. Khan F. Rehabilitation in Guillain Barre syndrome. Aust Fam Physician. 2004;33:1013–1017
  47. Garssen MP, Bussmann JB, Schmitz PI, et al. Physical training and fatigue, fitness, and quality of life in Guillain-Barre syndrome and CIDP. Neurology. 2004;63:2393–2395
  48. Strommen GL, Pucino F, Tight RR, Beck CL. Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment. Pharmacotherapy. 1988;8(1):52–68
  49. Carmichael JK. Treatment of herpes zoster and postherpetic neuralgia. Am Fam Physician. 1991;44:203–210
  50. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician. 2000;61:2437–2444
  51. Thorsteinsson G, Stonnington HH, Stillwell GK, Elveback LR. Transcutaneous electrical stimulation: a double-blind trial of its efficacy for pain. Arch Phys Med Rehabil. 1977;58:8–13
  52. Berciano J, Combarros O. Hereditary neuropathies. Curr Opin Neurol. 2003;16:613–622
  53. Bertorini T, Narayanaswami P, Rashed H. Charcot-Marie-Tooth disease (hereditary motor sensory neuropathies) and hereditary sensory and autonomic neuropathies. Neurologist. 2004;10:327–337
  54. Lee YC, Chang MH, Lin KP. Charcot-Marie-Tooth disease, Acta Neurol Taiwan. 2008;17(3):203–213[Chinese]
  55. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797–1810
  56. Tranchant C. Therapeutic strategy in myasthenia gravis, Rev Neurol (Paris). 2009;165(2):149–154[French]
  57. Sanders DB. Lambert-Eaton myasthenic syndrome: diagnosis and treatment. Ann N Y Acad Sci. 2003;998:500–508
  58. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104:359–363
  59. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. [see comment] N Engl J Med. 2001;344:1688–1700
  60. Wokke J. Riluzole. [see comment] Lancet. 1996;348:795–799
  61. Miller RG. Role of fatigue in limiting physical activities in humans with neuromuscular diseases. Am J Phys Med Rehabil. 2002;81(11 Suppl):S99–S107

PII: S0894-1130(09)00151-3

doi: 10.1016/j.jht.2009.11.003

Journal of Hand Therapy
Volume 23, Issue 2 , Pages 158-172 , April 2010

Article Tools

* Image Usage & Resolution